Contact Us

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells are expected to drive market growth

As per 2019 report by Leukemia and Lymphoma Society, 176,200 individuals in the U.S. are estimated to be diagnosed with leukemia, lymphoma or myeloma and approximately 1,399,180 individuals are living with leukemia, lymphoma or myeloma in the U.S. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. According to the Center for International Blood and Marrow Transplant Research reports nearly 101,433 Search Results hematopoietic cell transplantation were carried out in the U.S. between 2012 and 2016, which indicates potential opportunities for market players.

However, high costs associated with hematopoietic stem cell transplantation procedures are expected to hinder growth of the market. Other factors such as difficulty in finding a donor for allogeneic transplantation, technological barriers (currently used culture technologies, point of care delivery, and lack of analytical assay), and side effects such as graft vs. host disease, are also expected to slow down growth of the hematopoietic stem cell transplantation market.

Global Hematopoietic Stem Cell Transplantation Market Taxonomy

On the basis of indication:

  • Leukemia
  • Lymphatic disorder
  • Myeloma
  • Other non-malignant disorders (thalassemia, sickle cell anemia, Osteoporosis, Immunodeficiency syndrome)

On the basis of application:

  • Peripheral blood cells
  • Bone marrow
  • Umbilical cord blood

On the basis of Region:

  • North America
  • Europe
  • Middle East
  • Africa
  • Latin America
  • Asia Pacific

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017.

Furthermore, increasing strategic collaboration between leading players operating in the market is anticpated to propel the growth of the market during the forecast period. For instance, on January 2019, Gamida Cell Ltd. a leading cellular and immune therapeutics company, and Lonza entered into a strategic manufacturing agreement for commercial production after potential FDA approval of omidubicel, currently in clinical development designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant.

Important players present in the hematopoietic stem cell transplantation market

Major players operating in the hematopoietic stem cell transplantation market include Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner